CanAg® CA19-9 EIA

The CanAg CA19-9 EIA is based on a mouse monoclonal antibody, C192, highly specific for the sialyl Lewisa epitope, also known as CA19-9 antigen1.

In adults, the epitope is typically expressed in trace amounts on mucosal cells of gastrointestinal epithelia. In patients with malignant disease, the epitope may appear associated with high molecular weight mucin in blood. Assays for CA19-9 are frequently used to monitor gastrointestinal malignancies such as pancreatic, gall bladder, gastric, and colorectal cancers2, 3.


  1. Rye P. D. et al., (1998) Summary report on the ISOBM TD-6 workshop: Analysis of 20 monoclonal antibodies against Sialyl Lewisa and related antigens. Montreaux, Switzerland; September 19-24 1997. Tumor Biol. 19:390-420.

  2. Eskelinen M., and Haglund U. (1999) Developments in serologic detection of human pancreatic adenocarcinoma. Scand J Gastroenterol. 34: 833-844.

  3. Hammarström S., and Stigbrand T. (2002) Gastric Cancer. In “Tumor markers, Physiology, Pathobiology, Technology and Clinical Applications” Eds. Diamandis E. P. et al., AACC Press, Washington pp 375-379.

Contact sales for information
CE marked
CanAg CA19-9 EIA

Product number 120-10

For 96 determinations
Please contact your local Fujirebio representative for the availability of this product in your country.
  • Product inquiry

    The provision of your data implies your consent to the processing of your data in our database and, depending on the option you choose, to receiving our monthly newsletter by e-mail.

    For more information on how we process your personal data and regarding the rights you have in this respect, we refer to our privacy policy, which we hold at your disposal HERE.

    If you no longer wish to receive our newsletter, you have the option to unsubscribe via the ‘unsubscribe’ tool at the bottom of the newsletter. If you want to have your data removed from our database, please contact us at: